The future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how. Backed by True Ventures.
About the role
We are seeking a highly capable and proactive Senior Scientist, Peptide Discovery to join our Boston, MA team. This role reports to the Head of Gene Editing and Early Discovery and supports the experimental validation of AI-generated peptide candidates across multiple therapeutic programs — including but not limited to antifungal, antimicrobial, and cardiometabolic peptides — through cell culture-based functional, safety, and developability assays that directly inform our AI-guided peptide discovery pipeline. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Experience: A PhD in molecular biology, biochemistry, microbiology, genetics, bioengineering, or a life-sciences related field, or an MSc with equivalent hands-on laboratory experience
- Cell culture expertise: Strong, demonstrated hands-on experience with mammalian cell culture (aseptic technique, cell line maintenance, viability/cytotoxicity assays)
- Flow cytometry: Expertise in flow cytometry using both antibody panels and fluorescent reporters
- Microbiology (secondary): Basic familiarity with microbial/fungal handling, or willingness to be trained on it (not expected to be a core strength)
- Independence: Ability to work independently on multi-step, multi-day assay timelines
- Hemolysis & Membrane-Toxicity Assays: Experience with hemolysis assays or other peptide membrane-toxicity screens
More about this role
Basecamp Research is building frontier AI for therapeutic design. We believe the future of medicine lies in reprogramming the body to repair itself, and we design the models and the medicines to teach it how.
Our EDEN models are trained on BaseData, the world's largest proprietary genomic dataset, with over 10B genes collected through partnerships in more than 30 countries across all seven continents. This gives our AI models access to genetic diversity that doesn't exist in public databases, and enables EDEN to design cell and gene therapies, enzymes, and peptides directly from information about a disease. Our pipeline of EDEN-designed therapeutics, beginning with in vivo cell therapy, is advancing towards clinical development.
In September 2026 we closed an oversubscribed $140M Series C led by S32, with participation from NVIDIA, Anthropic's Anthology Fund, Catalio, European Tech Collective, Firebrand River Capital, King Philanthropies, NATO Innovation Fund, NVentures (NVIDIA's venture arm), Redalpine, Rockefeller Foundation, Singular, Sovereign AI and True Ventures. We have offices and labs in London and Boston, we partner with biopharma companies and academic institutions...
Browse similar: Startup jobs